Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 201–300 of 2,656
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 76
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, J., Pan, H., Shiao, C., Chuang, M., See, C. Y., Yeh, T.-H., Yang, Y., Chu, W.-K., & Wu, V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02035-8 · Cited by 51
“Among the 14 studies, four enrolled patients with empagliflozin [6, 9, 20, 27], and another three included patients with dapagliflozin [8, 28, 29].”
BackgroundHeart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
von Haehling, S., Aßmus, B., Bekfani, T., Dworatzek, E., Edelmann, F., Hashemi, D., Hellenkamp, K., Kempf, T., Raake, P., Schütt, K. A., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02396-4 · Cited by 53
Stewart, S., Kalra, P. A., Blakeman, T., Kontopantelis, E., Cranmer-Gordon, H., & Sinha, S. (2024) · BMC Medicine · doi:10.1186/s12916-024-03555-0 · Cited by 56
Causland, F. R. M., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Vardeny, O., Fang, J. C.-T., de Boer, R. A., Docherty, K. F., Hernandez, A. F., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4664 · Cited by 51
Zuliani, G., Zuin, M., Romagnoli, T., Polastri, M., Cervellati, C., & Brombo, G. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02675-6 · Cited by 52
Screening for chronic kidney disease: change of perspective and novel developments
van Mil, D., Kieneker, L. M., Heerspink, H. J. L., & Gansevoort, R. T. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001016 · Cited by 55
Lavalle, C., Mariani, M. V., Severino, P., Palombi, M., Trivigno, S., D’Amato, A., Silvetti, G., Pierucci, N., Lullo, L. D., Chimenti, C., et al. (2024) · Cardiorenal Medicine · doi:10.1159/000541393 · Cited by 45
Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism
Narongkiatikhun, P., Choi, Y. J., Hampson, H. E., Gotzamanis, J., Zhang, G., van Raalte, D. H., de Boer, I. H., Nelson, R. G., Tommerdahl, K. L., McCown, P. J., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.019 · Cited by 45
Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000248 · Cited by 40
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Thomas, M. C., Neuen, B. L., Twigg, S. M., Cooper, M. E., & Badve, S. V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0005 · Cited by 51
“Finally, the rate of decline in eGFR was significantly slowed following treatment with empagliflozin, with activity in all subgroups including participants without severely elevated albuminuria (49).”
InfluentialTangri, N., Ferguson, T. W., Bamforth, R. J., Leon, S. J., Arnott, C. G., Mahaffey, K. W., Kotwal, S. S., Heerspink, H. J. L., Perkovic, V., Fletcher, R. A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15678 · Cited by 48
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Rahman, H., Khan, S. U., Lone, A. N., Ghosh, P., Kunduru, M., Sharma, S., Sattur, S., & Kaluski, E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030578 · Cited by 46
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Yokose, C., McCormick, N., Abhishek, A., Dalbeth, N., Pascart, T., Lioté, F., Gaffo, A., FitzGerald, J. D., Terkeltaub, R. A., Sise, M. E., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01092-x · Cited by 47
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 47
Monzo, L., Ferrari, I., Cicogna, F., Tota, C., Cice, G., Girerd, N., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad055 · Cited by 43
Koh, E. S., Kim, G., & Chung, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1764 · Cited by 46
“Solid evidences, ranging from the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG OUTCOME) trial to The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY) trial, have indicated that SGLT2 inhibitors play major roles in slowing the progression…”
BackgroundNaas, S., Schiffer, M., & Schödel, J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00201.2023 · Cited by 49
Matteucci, A., Pandozi, C., Bonanni, M., Mariani, M. V., Sgarra, L., Nesti, L., Pierucci, N., Fazia, V. M. L., Lavalle, C., Nardi, F., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.09.023 · Cited by 49
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
“Study Name Drug Population CV Outcomes,HR (95% CI) Renal Outcomes, HR (95% CI) Renal outcomes trials CREDENCE [28] Canagliflozin Age ≥30 y with T2D and CKD d (N = 4401) MACE b: 0.80 (0.67–0.95) p = 0.01; CV death or HHF: 0.69 (0.57–0.83) p < 0.001; HHF: 0.61 (0.47–0.80) p < 0.001; CV death: 0.78 (0.61–1.00) p = 0.05 E…”
ResultInfluentialThe Fatty Kidney and Beyond: A Silent Epidemic
Seng, N. S. H. L., Lohana, P. J. D., Chandra, S., & Jim, B. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.06.025 · Cited by 39
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
Edmonston, D. L., Lydon, E. J., Mulder, H. S., Chiswell, K., Lampron, Z. M., Marsolo, K. A., Goss, A., Ayoub, I. M., Shah, R. C., Chang, A. R., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18808 · Cited by 46
Lu, C.-W., Lee, C., Hsieh, Y.-J., & Hsu, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210016 · Cited by 45
“73 m2, empagliflozin has been shown to decrease the likelihood of kidney disease advancement or cardiovascular-related mortality across a diverse population of individuals at risk for CKD progression [36].”
BackgroundObesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 52
Meregildo-Rodríguez, E. D., Asmat-Rubio, M. G., & Vásquez-Tirado, G. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1307715 · Cited by 45
Sperry, B., Sultan, M., Gundapaneni, B., Tai, S., & Witteles, R. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.02.007 · Cited by 35
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 43
Butt, J. H., Kondo, T., Yang, M., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Claggett, B. L., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad276 · Cited by 38
Liew, A., Lydia, A., Matawaran, B. J., Susantitaphong, P., Tran, H. T. B., & Lim, L. (2023) · Nephrology · doi:10.1111/nep.14167 · Cited by 42
Sivalingam, S., Wasehuus, V. S., Rotbain Curovic, V., Blond, M. B., Hansen, T. W., Persson, F., & Rossing, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15287 · Cited by 34
“4,9,10 Despite the success of SGLT2 inhibitors, this is often not sufficient to prevent progression of CKD.”
BackgroundUpdates on New Therapies for Patients with CKD
Tarun, T., Ghanta, S. N., Ong, V., Kore, R. A., Menon, L., Kovesdy, C. P., Mehta, J. L., & Jain, N. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.006 · Cited by 48
From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition
Zoccali, C., Mallamaci, F., Halimi, J., Rossignol, P., Sarafidis, P. A., Caterina, R. D., Giugliano, R. P., & Zannad, F. M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000361 · Cited by 48
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Costanzo, A. D., Esposito, G., Indolfi, C., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108732 · Cited by 44
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 45
Assessment and management of heart failure in patients with chronic kidney disease
Guaricci, A. I., Sturdà, F., Russo, R., Basile, P., Baggiano, A., Mushtaq, S., Fusini, L., Fazzari, F., Bertandino, F., Monitillo, F., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10346-x · Cited by 47
Mentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 41
“However, it has become evident that HFpEF is not a single entity, and patients with HFpEF are a heterogeneous group with a range of contributory conditions, such as atrial fibrillation, hypertensive heart disease, obesity, cardiac hypertrophy, and myocardial fibrosis (reviewed in [81]).”
BackgroundInfluentialEndpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 38
Iordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 37
“…discovery of the complex mechanisms that contribute to the development of renal dysfunction and the continuous research regarding innovative pharmacologic agents contribute significantly to attaining the ideal outcome of renal prevention and to a new dawn in the management of patients with CKD.”
BackgroundGuidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Theodorakopoulou, M. P., Ortíz, A., Fernández‐Fernández, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae278 · Cited by 56
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., Inzucchi, S. E., Lópes, R. D., McGuire, D. K., Lewis, J. B., Riddle, M. C., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00362-0 · Cited by 44
Malik, M. E., Butt, J. H., Strange, J. E., Falkentoft, A. C., Jensen, J., Andersson, C., Zahir, D., Fosbøl, E. L., Petrie, M. C., Sattar, N. A., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00164-2 · Cited by 34
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 42
Sridhar, V. S., Bhatt, D. L., Odutayo, A., Szarek, M. J., Davies, M. J., Banks, P. L., Pitt, B., Steg, P. G., & Cherney, D. Z. I. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000414 · Cited by 39
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 43
Heerspink, H. J. L., Stack, A. G., Terkeltaub, R. A., Jongs, N., Inker, L. A., Bjursell, M. K., Maklad, N. S., Perl, S., Eklund, O., Rikte, T., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000326 · Cited by 36
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Unraveling Sex Differences in Kidney Health and CKD: A Review of the Effect of Sex Hormones
van Eeghen, S. A., Nokoff, N., Vosters, T. G., Oosterom-Eijmael, M. J. P., Cherney, D. Z. I., van Valkengoed, I. G. M., Choi, Y. J., Pyle, L. L., Bjornstad, P., den Heijer, M., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000642 · Cited by 44
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 46
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, A., Raju, A. K. V., Gajjar, A. J., Menon, M., Shah, S. A. Y., Dani, S. S., & Weinberg, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13081924 · Cited by 49
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Fu, E. L., D’Andrea, E., Wexler, D. J., Patorno, E., & Paik, J. M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000115 · Cited by 40
“00 Metformin, n (%) 14,063 (44) 18,617 (29) 20.”
Possible renoprotective mechanisms of SGLT2 inhibitors
Nishiyama, A., & Kitada, K. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1115413 · Cited by 33
Gourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 35
“Three SGLT2is are recommended for nephroprotection in patients with T2DM, namely, canagliflozin, dapagliflozin, and empagliflozin, based on the results of the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) (55), DAPA-CKD (Dapagliflozin and Prevention of Adverse O…”
BackgroundNatale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 70
HOXD10 attenuates renal fibrosis by inhibiting NOX4-induced ferroptosis
Li, X., Ma, T., Wang, P., Shi, H., Hai, S., Qin, Y., Zou, Y., Zhu, W.-T., Li, H., Li, Y.-N., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06780-w · Cited by 41
Mayne, K. J., Sardell, R. J., Staplin, N., Judge, P. K., Zhu, D., Sammons, E. L., Cherney, D. Z. I., Cheung, A. K., Maggioni, A. P., Nangaku, M., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000498 · Cited by 37
Tangri, N., Álvarez, C. S., Arnold, M., Barone, S., Cebrián, A., Chen, H., Nicola, L. D., Järbrink, K., Kanumilli, N., Lim, K.-S., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14282 · Cited by 45
Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review
Cojuc‐Konigsberg, G., Güijosa, A., Moscona-Nissan, A., Nordmann-Gomes, A., Canaviri, V. A., Braverman-Poyastro, A., de la Fuente-Ramírez, R., Sánchez, D. N. T., Fuentes-Cepeda, A. D. L., Noyola‐Perez, A., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.06.012 · Cited by 39
Agarwal, A., Zeng, X., Li, S., Rayner, D. G., Foroutan, F., Aertgeerts, B., Coyac, F., Farhoumand, P. D., Demaine, A. G., Heen, A. F., et al. (2024) · BMJ · doi:10.1136/bmj-2024-080257 · Cited by 34
Gaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 44
Trionfetti, F., Marchant, V. A., Gónzalez-Mateo, G. T., Kawka, E., Márquez‐Expósito, L., Ortíz, A., López‐Cabrera, M., Ruiz‐Ortega, M., & Strippoli, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065763 · Cited by 36
Makmun, A., Satirapoj, B., Tuyen, D. G., Foo, M. W. Y., Danguilan, R. A., Gulati, S., Kim, S., Bavanandan, S., Chiu, Y., & Tang, S. C. W. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.23.194 · Cited by 45
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01877-6 · Cited by 34
“Recent studies on people with established chronic renal failure have proven that SGLT-2i effectively reduces cardiovascular fatality and a composite renal outcome [6, 7].”
BackgroundSGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
Klen, J., & Dolžan, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071995 · Cited by 38
Sarafidis, P. A., Schmieder, R. E., Burnier, M., Persu, A., Januszewicz, A., Halimi, J., Arıcı, M., Ortíz, A., Wanner, C., Mancia, G., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae041 · Cited by 35
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches
Frățilă, G., Lupusoru, G. E., Sorohan, B. M., Obrișcă, B., Mocanu, V., Lupușoru, M. O. D., & Ismail, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030569 · Cited by 51
Drug stewardship in chronic kidney disease to achieve effective and safe medication use
Hall, R. K., Kazancıoğlu, R., Thanachayanont, T., Wong, G., Sabanayagam, D., Battistella, M., Ahmed, S. B., Inker, L. A., Barreto, E. F., Fu, E. L., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00823-3 · Cited by 43
Chaudhry, K., & Karalliedde, J. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15765 · Cited by 42
Groß, O., Boeckhaus, J., Weber, L. T., Heerspink, H. J. L., Simon, J. F., Ahmed, R., Gerst, C., Duerr, U., Walker, F., Tostmann, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae180 · Cited by 40
Advances in kidney disease: pathogenesis and therapeutic targets
Boima, V., Agyekum, A. B., Ganatra, K., Agyekum, F., Kwakyi, E. P. K., Inusah, J., Ametefe, E. N., & Adu, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1526090 · Cited by 43
Bakker, W. M., Heerspink, H. J. L., Berger, S. P., Wanner, C., Badve, S. V., Arnott, C. G., Abrahams, A. C., van den Born, J. C., van Faassen, T. C., Gaillard, S., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf046 · Cited by 51
“Of note, similar composite endpoints have been applied in other trials investigating SGLT2 inhibitors, such as the DAPA-CKD, CREDENCE, EMPA-KIDNEY and the EMPEROR-Preserved trials (NCT03057951) [7 , 8 , 6 , 20 ].”
InfluentialSGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
Wing, S., Ray, J. G., Yau, K., Jeyakumar, N., Abdullah, S., Luo, B., Cherney, D. Z. I., Harel, Z., Hundemer, G. L., Mavrakanas, T. A., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.0686 · Cited by 29
IgA Nephropathy: Current Treatment and New Insights
Petrou, D., Kalogeropoulos, P. G., Liapis, G., & Lionaki, S. (2023) · Antibodies · doi:10.3390/antib12020040 · Cited by 37
“Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo [34].”
BackgroundDiallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02154-4 · Cited by 38
Kale, A., Shelke, V., Lei, Y., Gaikwad, A. B., & Anders, H. (2023) · Cells · doi:10.3390/cells12202440 · Cited by 28
Verma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 30
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
Dilemmas in the diagnosis and management of antiphospholipid syndrome
Manning, J. E., & Arachchillage, D. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.027 · Cited by 39
Longhitano, E., Calabrese, V., Casuscelli, C., Carlo, S. D., Maltese, S., Romeo, A., Calanna, M., Conti, G., & Santoro, D. (2024) · Medicina · doi:10.3390/medicina60111821 · Cited by 46
“The 2023 UK guidelines, in fact, recommend using SGLT2i in people with or without type 2 diabetes with UACR ≥ 200 mg/g and eGFR ≥ 20 mL/min/1.73 m 2 [40].”
InfluentialLan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 42
Risk-directed management of chronic kidney disease
Blum, M. F., Neuen, B. L., & Grams, M. E. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00931-8 · Cited by 39
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Heerspink, H. J. L., Collier, W., Chaudhari, J., Miao, S., Tighiouart, H., Appel, G. B., Caravaca‐Fontán, F., Floege, J., Hannedouche, T. P., Imai, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04057-z · Cited by 49
“In a sensitivity analysis, we included two recent studies for which we received from the clinical trial investigators only tabular data but not individual participant data 17,18 .”
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 32
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 31
“In contrast to EMPA-REG-OUTCOME, subgroup analysis of patients with albuminuria < 30 mg/g showed no significant effect on the primary outcome, but the decline in eGFR was nevertheless reduced in these individuals [75].”
ResultSridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
2023 Clinical Practice Guidelines for Diabetes
Moon, M. K. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.120 · Cited by 27
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 38
Morioka, F., Nakatani, S., Uedono, H., Tsuda, A., Mori, K., & Emoto, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196341 · Cited by 29
“Furthermore, results from the DAPA-CKD and EMPA-Kidney trials demonstrated the clinical benefits of SGLT2 inhibitors for improving CVD outcomes in CKD patients [8,10].”
BackgroundMethodResultInfluentialNeuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100988 · Cited by 34
Fadini, G. P., Longato, E., Morieri, M. L., Prato, S. D., Avogaro, A., Solini, A., Baldassarre, M., Consoli, A., Morganet, S., Zugaro, A., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100847 · Cited by 34
Mirioğlu, Ş., Daniel-Fischer, L., Berke, İ., Ahmad, S. H., Bajema, I. M., Bruchfeld, A. N., Juarez, G. M. F., Floege, J., Frangou, E. A., Goumenos, D. S., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae025 · Cited by 35
“The use of sodium-glucose transporter-2 inhibitors (SGLT2i) has changed the standard of care concept in CKD. DAPA-CKD and EMPA-KIDNEY trials demonstrated the efficacy of SGLT2i in decreasing the progression of CKD with proteinuria in patients with and without diabetes [59 , 60 ].”
BackgroundGreen, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 30
Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect
Yau, K., Cherney, D. Z. I., van Raalte, D. H., & Wever, B. E. (2024) · Kidney International · doi:10.1016/j.kint.2024.03.019 · Cited by 35
Matsui, S., Yamamoto, T., Takabatake, Y., Takahashi, A., Namba‐Hamano, T., Matsuda, J., Minami, S., Sakai, S., Yonishi, H., Nakamura, J., et al. (2024) · Autophagy · doi:10.1080/15548627.2024.2410621 · Cited by 31
“Our findings may explain the essential mechanism underlying renoprotection mediated by SLC5A2 inhibition, not only in albuminuric DKD but also in nonalbuminuric advanced CKD, as recently reported in the EMPA-KIDNEY trial [6].”
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 41
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.